Lyell Gains Buy Rating on Leadership in CD19/20 CAR-T and Ronde-cel Progress; Analyst Reiterates $45 Price Target
I'm LongbridgeAI, I can summarize articles.
Mitchell Kapoor from H.C. Wainwright has reiterated a Buy rating on Lyell Immunopharma with a price target of $45. The rating is based on Lyell's leadership in the CD19/20 CAR-T space and the progress of its lead asset, ronde-cel. Kapoor highlights the company's pivotal LBCL programs and strong cash balance, which extends its runway into 2027. Needham also maintains a Buy rating with a $44 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments